Free Trial
OTCMKTS:NVZMY

Novozymes A/S (NVZMY) Stock Price, News & Analysis

Novozymes A/S logo
$59.38 +1.92 (+3.34%)
(As of 11/22/2024 ET)

About Novozymes A/S Stock (OTCMKTS:NVZMY)

Key Stats

Today's Range
$59.22
$59.80
50-Day Range
$55.30
$72.01
52-Week Range
$49.99
$72.50
Volume
22,099 shs
Average Volume
12,779 shs
Market Capitalization
$27.81 billion
P/E Ratio
37.58
Dividend Yield
1.11%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Novozymes A/S Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
79th Percentile Overall Score

NVZMY MarketRank™: 

Novozymes A/S scored higher than 79% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Novozymes A/S are expected to grow by 17.58% in the coming year, from $1.82 to $2.14 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novozymes A/S is 37.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novozymes A/S is 37.58, which means that it is trading at a less expensive P/E ratio than the Basic Materials sector average P/E ratio of about 113.41.

  • Price to Earnings Growth Ratio

    Novozymes A/S has a PEG Ratio of 3.87. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novozymes A/S has a P/B Ratio of 13.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Novozymes A/S have been sold short.
  • Short Interest Ratio / Days to Cover

    Novozymes A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novozymes A/S has recently decreased by 14.29%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Novozymes A/S pays a meaningful dividend of 1.17%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novozymes A/S does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novozymes A/S is 41.77%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 30.84% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.

  • Read more about Novozymes A/S's dividend.
  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Novozymes A/S have been sold short.
  • Short Interest Ratio / Days to Cover

    Novozymes A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novozymes A/S has recently decreased by 14.29%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Novozymes A/S has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Basic Materials companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Novozymes A/S this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Novozymes A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Stock News Headlines

Novonesis Reports Strong Q3 Growth in 2024
2024 Election Year Stocks: Uncover Hidden Gems!
In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.
What Wall Street expects from Novozymes A-S (B)'s earnings
Novozymes A-S (B) Un earnings: here's what to expect
Novozymes A/S B (NSISb)
Novozymes A/S (NSISBC.XC)
See More Headlines

NVZMY Stock Analysis - Frequently Asked Questions

Novozymes A/S's stock was trading at $54.9050 at the start of the year. Since then, NVZMY shares have increased by 8.2% and is now trading at $59.38.
View the best growth stocks for 2024 here
.

Novozymes A/S (OTCMKTS:NVZMY) issued its quarterly earnings results on Wednesday, January, 31st. The biotechnology company reported $0.36 earnings per share for the quarter, missing analysts' consensus estimates of $0.47 by $0.11. The biotechnology company earned $664.46 million during the quarter.

The following companies are subsidiaries of Novozymes A/S: PrecisionBiotics Group Limited, OrganoBalance GmbH, Pacific Vet Group-USA, Allopartis, TJ Technologies, Iogen Bio-Products, Natural Industries, and more.

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
1/31/2024
Ex-Dividend for 9/18 Dividend
9/09/2024
Dividend Payable
9/18/2024
Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:NVZMY
Employees
6,756
Year Founded
2000

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.60 billion
Cash Flow
$0.82 per share
Book Value
$4.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$27.81 billion
Optionable
Not Optionable
Beta
0.90

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (OTCMKTS:NVZMY) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners